

Annex II

Condition for lifting the suspension of the marketing authorisation

Condition for lifting the suspension of the marketing authorisation

For the suspension to be lifted, the marketing authorisation holder shall submit robust evidence that defines a clinically relevant patient population in which the benefit-risk balance of the treatment is favourable.

Medicinal product no longer authorised